Xencor Inc. (XNCR) Shares Bought by JPMorgan Chase & Co.
JPMorgan Chase & Co. increased its stake in Xencor Inc. (NASDAQ:XNCR) by 106.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 288,950 shares of the biopharmaceutical company’s stock after buying an additional 149,050 shares during the period. JPMorgan Chase & Co. owned 0.71% of Xencor worth $5,487,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Metropolitan Life Insurance Co. NY boosted its stake in shares of Xencor by 5.1% in the first quarter. Metropolitan Life Insurance Co. NY now owns 21,213 shares of the biopharmaceutical company’s stock valued at $285,000 after buying an additional 1,026 shares in the last quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp acquired a new stake in shares of Xencor during the second quarter valued at about $414,000. DekaBank Deutsche Girozentrale boosted its stake in shares of Xencor by 24.1% in the second quarter. DekaBank Deutsche Girozentrale now owns 23,700 shares of the biopharmaceutical company’s stock valued at $439,000 after buying an additional 4,600 shares in the last quarter. Strs Ohio boosted its stake in shares of Xencor by 301.1% in the second quarter. Strs Ohio now owns 36,500 shares of the biopharmaceutical company’s stock valued at $693,000 after buying an additional 27,400 shares in the last quarter. Finally, Emerald Acquisition Ltd. acquired a new stake in shares of Xencor during the second quarter valued at about $960,000. 67.44% of the stock is owned by institutional investors.
Shares of Xencor Inc. (NASDAQ:XNCR) traded up 0.23% during mid-day trading on Thursday, reaching $21.38. 46,018 shares of the company traded hands. Xencor Inc. has a 52-week low of $9.89 and a 52-week high of $26.50. The company has a market capitalization of $875.49 million, a P/E ratio of 22.72 and a beta of 2.11. The firm’s 50 day moving average price is $23.04 and its 200-day moving average price is $17.64.
Xencor (NASDAQ:XNCR) last announced its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $1.31. Xencor had a return on equity of 22.53% and a net margin of 39.07%. The company had revenue of $66 million for the quarter, compared to analyst estimates of $7.43 million. Equities analysts predict that Xencor Inc. will post $0.56 earnings per share for the current fiscal year.
Several analysts have recently issued reports on the stock. Piper Jaffray Cos. assumed coverage on shares of Xencor in a research report on Tuesday, October 4th. They set an “overweight” rating and a $35.00 price target on the stock. Canaccord Genuity set a $27.00 price target on shares of Xencor and gave the stock a “buy” rating in a research report on Monday, September 12th. Zacks Investment Research cut shares of Xencor from a “buy” rating to a “hold” rating in a research report on Wednesday, August 31st. Wedbush reissued an “outperform” rating and set a $27.00 price target on shares of Xencor in a research report on Monday, September 12th. Finally, Leerink Swann reissued an “outperform” rating and set a $18.00 price target on shares of Xencor in a research report on Wednesday, June 29th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $25.14.
In other Xencor news, major shareholder John S. Stafford III sold 30,500 shares of the company’s stock in a transaction that occurred on Thursday, August 11th. The stock was sold at an average price of $21.87, for a total value of $667,035.00. Following the transaction, the insider now directly owns 7,500 shares of the company’s stock, valued at approximately $164,025. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP John R. Desjarlais sold 5,905 shares of the company’s stock in a transaction that occurred on Wednesday, August 3rd. The shares were sold at an average price of $20.00, for a total value of $118,100.00. The disclosure for this sale can be found here. 4.03% of the stock is owned by company insiders.
Xencor Company Profile
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. Its segment is related to the development of pharmaceutical products. It uses its XmAb technology platform to create antibody product candidates designed to treat autoimmune and allergic diseases, cancer and other conditions.
Want to see what other hedge funds are holding XNCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xencor Inc. (NASDAQ:XNCR).
Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.